| Group A versus Group B |  | Group C versus Group D | ||
---|---|---|---|---|---|
OR (95% Cl) | p | OR (95% Cl) | p | ||
Tumor stage* | Â | 0.072 | Tumor stage* | Â | 0.023 |
 II | 0.14 (0.02–1.20) |  |  II | 0.39 (0.17–0.88) |  |
 III + IV | Ref |  |  III + IV | Ref |  |
Consolidation chemo cycles |  | 0.421 | Consolidation chemo cycles | – | – |
 2 cycles | 1.70 (0.47–6.16) |  |  2 cycles |  |  |
 0–1 cycle | Ref |  |  0–1 cycle |  |  |
Bone marrow V5 | Â | 0.027 | Bone Marrow V5 | Â | 0.025 |
 ≥ 40.7% | 4.24 (1.18–15.20) |  |   ≥ 46.0% | 2.29 (1.11–4.73) |  |
 < 40.7% | Ref |  |   < 46.0% | Ref |  |
EDIC | – | – | EDIC |  | 0.460 |
 ≥ 11.8 Gy |  |  |   ≥ 10.3 Gy | 1.32 (0.63–2.78) |  |
 < 11.8 Gy |  |  |   < 10. 3 Gy | Ref |  |